Physician profile
Donald L Lamm
NPI 1760577639
$80,250.12
in general payments reported to CMS, 2019-2025
15 companies · $6,599 in 2025
The $6,599 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $15K · 2021: $14K · 2022: $15K · 2023: $253 · 2024: $7,533 · 2025: $6,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $14K · Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $14,088.25 |
| Food and Beverage | $295.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $70,032.34 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $6,966.87 | 2019 | |
| Aadi Bioscience, INC. | $1,500.00 | 2022 | |
| Nonagen Bioscience Corp | $875.00 | 2022 | |
| Astellas Pharma US INC | $240.10 | 2019-2024 | Xtandi |
| Janssen Biotech, INC. | $134.76 | 2019 | |
| Innovation Technologies INC | $116.02 | 2023 | Irrisept |
| Comsort, INC | $100.00 | 2019 | |
| Coloplast Corp | $93.67 | 2023 | |
| Procept Biorobotics Corporation | $79.63 | 2022 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Urogen Pharma, INC. | $26.76 | 2022 | |
| Janssen Scientific Affairs, LLC | $25.98 | 2019 | |
| Blue Earth Diagnostics | $16.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.